On Apr. 30, 2025, Regulus Therapeutics announced that it has entered into an agreement and plan of merger with Novartis, pursuant to which Novartis will acquire Regulus for an initial payment of $7.00 per share in cash at closing, or $0.8 billion.

Regulus Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.

The upfront cash portion of the consideration represents a premium of 274 percent to Regulus’ 60-day volume-weighted average stock price and 108 percent to Regulus’ closing price on April 29, 2025.

In addition, Regulus shareholders will receive a contingent value right (CVR) providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus’ lead product candidate, farabursen.

Total consideration including the CVR, if the milestone is achieved, would be approximately $1.7 billion. The transaction has been unanimously approved by the Boards of Directors of both companies.